metaEvidence - overview


			deaths (OS)
mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1)
mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.89 [0.76; 1.05], 1 RCT, I2=0% inconclusive result
versus Standard of Care (SoC)
	atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC)	1	0.86 [0.72; 1.02], 1 RCT, I2=0% inconclusive result
	atezolizumab plus paclitaxel vs. Standard of Care (SoC)	1	1.12 [0.88; 1.43], 1 RCT, I2=0% inconclusive result
mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	2	0.82 [0.70; 0.95], 2 RCTs, I2=0% conclusive high degree of certainty
versus Standard of Care (SoC)
	atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC)	1	0.71 [0.54; 0.94], 1 RCT, I2=0% unassessable degree of certainty
	atezolizumab plus paclitaxel vs. Standard of Care (SoC)	1	1.11 [0.76; 1.63], 1 RCT, I2=0% inconclusive result